You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
30 January 2026 - Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN) said on Friday that it has entered into a strategic collaboration with CSPC Pharmaceuticals to advance eight programmes targeting obesity and type 2 diabetes...
30 January 2026 - Biotechnology company Repertoire Immune Medicines announced on Thursday that it has entered into a strategic collaboration with pharmaceutical company Eli Lilly and Company (NYSE:LLY) to develop tolerizing therapies for multiple aut...
30 January 2026 - Formation Bio, an AI-native pharma company, and Chinese pharmaceutical company Jiangsu Chia Tai Feng Hai Pharmaceutical Co Ltd (CTFH) announced on Thursday that Formation Bio has acquired worldwide rights, excluding Greater China, t...
29 January 2026 - Biopharmaceutical oncology company Summit Therapeutics Inc (NASDAQ:SMMT) announced on Thursday that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for ivonescimab in combination with c...
29 January 2026 - Spanish pharmaceutical company Almirall, S.A. (BME:ALM) announced on Thursday that China's National Medical Products Administration (NMPA) has approved Seysara (sarecycline hydrochloride) for the treatment of inflammatory lesio...
29 January 2026 - Global biotechnology company Alvotech S.A. (NASDAQ:ALVO) announced on Thursday that it has entered into a licensing and settlement agreement with US biotechnology company Regeneron Pharmaceuticals Inc (Nasdaq:REGN) and German pharma...
29 January 2026 - French biotechnology company OSE Immunotherapeutics SA (Euronext Paris:OSE) said on Thursday that it has selected chronic pouchitis and hidradenitis suppurativa as new key clinical indications for its IL-7R antagonist lusvertikimab ...